OverviewSuggest Edit

Clearside Biomedical is a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. It provides a non-surgical application for dosing drugs to distinct eye tissues, such as retina, trabecular meshwork, and corneal stroma. The Сompany’s CLS1001 is under development for retinal applications through the delivery of therapeutics to the suprachoroidal space.

TypePublic
Founded2011
HQAlpharetta, US
Websiteclearsidebio.com

Latest Updates

Employees (est.) (Dec 2019)33(-34%)
Revenue (FY, 2019)$2.2 M(+7144%)
Share Price (Sept 2020)$1.7 (+3%)
Cybersecurity ratingAMore

Key People/Management at Clearside Biomedical

Charles A. Deignan

Charles A. Deignan

Chief Financial Officer
Rafael V. Andino

Rafael V. Andino

Vice President, Engineering & Manufacturing
William D. Humphries

William D. Humphries

Chairperson
Richard Croarkin

Richard Croarkin

Director
George Lasezkay

George Lasezkay

President and Chief Executive Officer, Director
Rick McElheny

Rick McElheny

Vice President, Business Development
Show more

Clearside Biomedical Office Locations

Clearside Biomedical has an office in Alpharetta
Alpharetta, US (HQ)
900 North Point Pkwy
Show all (1)

Clearside Biomedical Financials and Metrics

Clearside Biomedical Revenue

Clearside Biomedical's revenue was reported to be $2.17 m in FY, 2019
USD

Revenue (Q2, 2020)

354.0k

Net income (Q2, 2020)

(5.8m)

EBIT (Q2, 2020)

(5.6m)

Market capitalization (18-Sept-2020)

82.7m

Closing stock price (18-Sept-2020)

1.7

Cash (30-Jun-2020)

15.1m

EV

68.6m
Clearside Biomedical's current market capitalization is $82.7 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

520.0k345.0k30.0k2.2m

Revenue growth, %

(34%)

General and administrative expense

6.6m6.3m9.7m14.7m16.8m

R&D expense

10.8m19.5m49.1m68.3m15.7m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

5.0k5.0k5.0k130.0k155.0k45.0k45.0k141.0k4.1m354.0k

General and administrative expense

970.0k1.6m2.7m2.3m2.3m3.6m3.9m4.4m5.0m3.8m3.1m2.6m

R&D expense

4.2m3.7m7.6m11.5m16.1m17.3m20.1m11.0m658.0k2.7m3.8m3.3m

Operating expense total

5.2m5.3m10.3m13.8m18.3m20.9m24.0m15.4m5.7m6.5m6.9m5.9m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

20.3m34.8m9.2m8.0m22.6m

Prepaid Expenses

159.0k396.0k1.4m2.0m1.1m

Current Assets

20.5m84.3m39.2m42.9m25.2m

PP&E

156.0k94.0k885.0k790.0k541.0k
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(17.6m)(25.9m)(59.0m)(82.8m)(30.8m)

Depreciation and Amortization

60.0k65.0k182.0k189.0k211.0k

Accounts Payable

632.0k1.4m4.7m(314.0k)(5.6m)

Cash From Operating Activities

(13.9m)(22.7m)(51.1m)(79.2m)(27.1m)
USDFY, 2015

Financial Leverage

-0.6 x
Show all financial metrics

Clearside Biomedical Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Clearside Biomedical Online and Social Media Presence

Embed Graph

Clearside Biomedical News and Updates

Clearside Biomedical Establishes Scientific Advisory Board with Distinguished Retinal Physicians

ALPHARETTA, Ga., April 09, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today the formation of a Scientif…

Clearside Biomedical to Present at the Needham Virtual Healthcare Conference

ALPHARETTA, Ga., April 08, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm…

Clearside Biomedical to Present at Two Upcoming Investor Conferences in March 2020

ALPHARETTA, Ga., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the Company will presen…

Bausch Health, Clearside Biomedical publish data on eye drug

Shares of Bausch Health Companies Inc. were up 0.3% in premarket trading on Tuesday after it announced the publication of late-stage trial data for an investigational eye therapy it is developing with Clearside Biomedical Inc. . Clearside's stock was up 9%. The experimental therapy, Xipere, is bein…

Clearside Biomedical Featured at Multiple European Scientific Retinal Congresses

ALPHARETTA, Ga., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that numerous presentations…

Clearside Biomedical to Present at the 2019 Wedbush PacGrow Healthcare Conference

ALPHARETTA, Ga., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer…
Show more

Clearside Biomedical Frequently Asked Questions

  • When was Clearside Biomedical founded?

    Clearside Biomedical was founded in 2011.

  • Who are Clearside Biomedical key executives?

    Clearside Biomedical's key executives are Charles A. Deignan, Rafael V. Andino and William D. Humphries.

  • How many employees does Clearside Biomedical have?

    Clearside Biomedical has 33 employees.

  • What is Clearside Biomedical revenue?

    Latest Clearside Biomedical annual revenue is $2.2 m.

  • What is Clearside Biomedical revenue per employee?

    Latest Clearside Biomedical revenue per employee is $65.8 k.

  • Who are Clearside Biomedical competitors?

    Competitors of Clearside Biomedical include Vertex Pharmaceuticals, Marinus Pharmaceuticals and Selecta Biosciences.

  • Where is Clearside Biomedical headquarters?

    Clearside Biomedical headquarters is located at 900 North Point Pkwy, Alpharetta.

  • Where are Clearside Biomedical offices?

    Clearside Biomedical has an office in Alpharetta.

  • How many offices does Clearside Biomedical have?

    Clearside Biomedical has 1 office.